STOCKHOLM, Nov. 1, 2018 /PRNewswire/ -- NefIgArd Phase 3-study initiated according to plan "This quarter, the company went into execution mode with regards to the preparations related to our clinical Phase 3 study NefIgArd. We were excited to get going after receiving the...
from PR Newswire: //https://ift.tt/2OkUkOt
No comments:
Post a Comment